Literature DB >> 17608662

Evaluation of disease activity markers in dogs with idiopathic inflammatory bowel disease.

T M McCann1, A E Ridyard, R W Else, J W Simpson.   

Abstract

OBJECTIVES: To evaluate the clinical utility of serum tumour necrosis factor-alpha, C-reactive protein and microalbuminuria as disease activity markers in canine idiopathic inflammatory bowel disease.
METHODS: Dogs with chronic gastrointestinal disease for which no underlying cause could be identified were considered to have idiopathic inflammatory bowel disease and were included in the study. Serum tumour necrosis factor-alpha was assessed using a canine-specific ELISA, C-reactive protein by immunoturbidometric assay and quantitative microalbuminuria was analysed using a monoclonal antibody directed against canine albumin. The canine inflammatory bowel disease activity index and histopathologic grade were used to assess disease severity; biologic markers were then compared with the canine inflammatory bowel disease activity index and histopathologic grade.
RESULTS: Sixteen dogs were included in the study. C-reactive protein level was mildly elevated in 15 dogs. Microalbuminuria was elevated in two of 15 dogs, and tumour necrosis factor-alpha was not detected in any dog tested. No correlation was found between the canine inflammatory bowel disease activity index and C-reactive protein or microalbuminuria or between histopathologic grade and C-reactive protein or microalbuminuria. There was no correlation between histopathologic grade and the canine inflammatory bowel disease activity index. CLINICAL SIGNIFICANCE: Although only a small number of dogs were evaluated, this study does not support the use of serum tumour necrosis factor-alpha measured by canine-specific ELISA or microalbuminuria in the evaluation of disease activity in dogs with idiopathic inflammatory bowel disease. Although mildly elevated in most dogs, C-reactive protein did not reflect disease severity as assessed by the canine inflammatory bowel disease activity index or histopathologic grade.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608662     DOI: 10.1111/j.1748-5827.2007.00335.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  10 in total

Review 1.  Inflammatory bowel disease in the dog: differences and similarities with humans.

Authors:  Matteo Cerquetella; Andrea Spaterna; Fulvio Laus; Beniamino Tesei; Giacomo Rossi; Elisabetta Antonelli; Vincenzo Villanacci; Gabrio Bassotti
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

2.  Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial.

Authors:  Sergi Segarra; Silvia Martínez-Subiela; Marta Cerdà-Cuéllar; Daniel Martínez-Puig; Alberto Muñoz-Prieto; Fernando Rodríguez-Franco; Antonio Rodríguez-Bertos; Karin Allenspach; Alfonso Velasco; José Cerón
Journal:  BMC Vet Res       Date:  2016-03-10       Impact factor: 2.741

3.  Determining optimal therapy of dogs with chronic enteropathy by measurement of serum citrulline.

Authors:  Magda Gerou-Ferriani; Rhiannon Allen; Peter-John M Noble; Alexander J German; Marco Caldin; Daniel J Batchelor
Journal:  J Vet Intern Med       Date:  2018-04-16       Impact factor: 3.333

4.  Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease.

Authors:  Cristiane C Otoni; Romy M Heilmann; Mercedes García-Sancho; Angel Sainz; Mark R Ackermann; Jan S Suchodolski; Jörg M Steiner; Albert E Jergens
Journal:  J Vet Intern Med       Date:  2018-04-06       Impact factor: 3.333

5.  Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies.

Authors:  Romy M Heilmann; Nora Berghoff; Joanne Mansell; Niels Grützner; Nolie K Parnell; Corinne Gurtner; Jan S Suchodolski; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2018-02-20       Impact factor: 3.333

Review 6.  Comparative pathophysiology and management of protein-losing enteropathy.

Authors:  Melanie D Craven; Robert J Washabau
Journal:  J Vet Intern Med       Date:  2019-02-14       Impact factor: 3.333

7.  Colonic mucosal and cytobrush sample cytokine mRNA expression in canine inflammatory bowel disease and their correlation with disease activity, endoscopic and histopathologic score.

Authors:  Alexandros O Konstantinidis; Katerina K Adamama-Moraitou; Dimitra Pardali; Chrysostomos I Dovas; Georgia D Brellou; Theologos Papadopoulos; Albert E Jergens; Karin Allenspach; Timoleon S Rallis
Journal:  PLoS One       Date:  2021-01-20       Impact factor: 3.240

Review 8.  Canine chronic enteropathy-Current state-of-the-art and emerging concepts.

Authors:  Albert E Jergens; Romy M Heilmann
Journal:  Front Vet Sci       Date:  2022-09-21

9.  The characteristics of short- and long-term surviving Shiba dogs with chronic enteropathies and the risk factors for poor outcome.

Authors:  Hiroki Okanishi; Tadashi Sano; Yoshiki Yamaya; Yumiko Kagawa; Toshihiro Watari
Journal:  Acta Vet Scand       Date:  2013-04-17       Impact factor: 1.695

Review 10.  Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs.

Authors:  Romy M Heilmann; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2018-09-17       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.